FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W197747024> ?p ?o ?g. }

• W197747024 endingPage "129" @default.
• W197747024 startingPage "120" @default.
• W197747024 abstract "BACKGROUND: Oral antihyperglycemic drugs used to treat type 2 diabetes mellitus (T2DM) vary in safety and tolerability. Treatment-related hypoglycemia and weight gain can exacerbate underlying disease. OBJECTIVE: To evaluate the tolerability of saxagliptin using data from phase III clinical trials. METHODS: Six 24-week randomized studies in 4,214 patients with T2DM were assessed. Saxagliptin 2.5 mg or 5 mg was compared with placebo in 2 trials of monotherapy in treatment-naïve patients and in 3 trials of add-on therapy to metformin, glyburide, or a thiazolidinedione; initial combination therapy with saxagliptin 5 mg plus metformin was compared with metformin monotherapy in treatment-naïve patients. Data from the monotherapy and add-on studies were pooled; data from the initial combination study were analyzed separately. No statistical analyses of between-group comparisons across studies were conducted for these safety analyses because of multiplicity of end points and relative lack of statistical power and because small differences not reaching statistical significance have the potential to be clinically relevant. RESULTS: In the pooled analysis, incidence rates for adverse events (AEs) with saxagliptin 2.5 mg, 5 mg, and placebo were 72.0% (635/882), 72.2% (637/882), and 70.6% (564/799), respectively; rates for serious AEs (SAEs) were 3.5% (31/882), 3.4% (30/882), and 3.4% (27/799); rates of discontinuation due to AEs were 2.2% (19/882), 3.3% (29/882), and 1.8% (14/799). AEs reported in ≥ 2% of patients receiving saxagliptin and occurring ≥ 1% more frequently with saxagliptin than with placebo were sinusitis, gastroenteritis, abdominal pain, and vomiting. In the initial combination study, AE incidence rates with saxagliptin 5 mg plus metformin and metformin monotherapy were 55.3% (177/320) and 58.5% (192/328), respectively; incidence rates for SAEs were 2.5% (8/320) and 2.4% (8/328); and rates of discontinuation due to AEs were 2.5% (8/320) and 3.4% (11/328). CONCLUSION: Saxagliptin 2.5 mg or 5 mg was generally well tolerated as monotherapy, add-on combination therapy with other oral antihyperglycemic drugs, and initial combination with metformin." @default.
• W197747024 created "2016-06-24" @default.
• W197747024 creator A5081667069 @default.
• W197747024 date "2014-02-01" @default.
• W197747024 modified "2023-10-01" @default.
• W197747024 title "Tolerability of Saxagliptin in Patients with Inadequately Controlled Type 2 Diabetes: Results from 6 Phase III Studies" @default.
• W197747024 cites W1970125713 @default.
• W197747024 cites W1971471384 @default.
• W197747024 cites W1982311681 @default.
• W197747024 cites W2012437459 @default.
• W197747024 cites W2020292843 @default.
• W197747024 cites W2040643300 @default.
• W197747024 cites W2042702624 @default.
• W197747024 cites W2045063167 @default.
• W197747024 cites W2045923887 @default.
• W197747024 cites W2048728983 @default.
• W197747024 cites W2099673402 @default.
• W197747024 cites W2108646121 @default.
• W197747024 cites W2111152015 @default.
• W197747024 cites W2111876001 @default.
• W197747024 cites W2115360698 @default.
• W197747024 cites W2123355624 @default.
• W197747024 cites W2126065052 @default.
• W197747024 cites W2127125241 @default.
• W197747024 cites W2131490500 @default.
• W197747024 cites W2146901298 @default.
• W197747024 cites W2162037642 @default.
• W197747024 cites W2176774871 @default.
• W197747024 cites W2772390855 @default.
• W197747024 doi "https://doi.org/10.18553/jmcp.2014.20.2.120" @default.
• W197747024 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24456313" @default.
• W197747024 hasPublicationYear "2014" @default.
• W197747024 type Work @default.
• W197747024 sameAs 197747024 @default.
• W197747024 citedByCount "8" @default.
• W197747024 countsByYear W1977470242015 @default.
• W197747024 countsByYear W1977470242016 @default.
• W197747024 countsByYear W1977470242017 @default.
• W197747024 countsByYear W1977470242018 @default.
• W197747024 countsByYear W1977470242020 @default.
• W197747024 crossrefType "journal-article" @default.
• W197747024 hasAuthorship W197747024A5081667069 @default.
• W197747024 hasBestOaLocation W1977470242 @default.
• W197747024 hasConcept C126322002 @default.
• W197747024 hasConcept C134018914 @default.
• W197747024 hasConcept C142724271 @default.
• W197747024 hasConcept C197934379 @default.
• W197747024 hasConcept C204787440 @default.
• W197747024 hasConcept C27081682 @default.
• W197747024 hasConcept C2777180221 @default.
• W197747024 hasConcept C2778375690 @default.
• W197747024 hasConcept C2778715236 @default.
• W197747024 hasConcept C2778763485 @default.
• W197747024 hasConcept C2779284873 @default.
• W197747024 hasConcept C2779306644 @default.
• W197747024 hasConcept C2780282729 @default.
• W197747024 hasConcept C2780323712 @default.
• W197747024 hasConcept C555293320 @default.
• W197747024 hasConcept C71924100 @default.
• W197747024 hasConcept C98274493 @default.
• W197747024 hasConceptScore W197747024C126322002 @default.
• W197747024 hasConceptScore W197747024C134018914 @default.
• W197747024 hasConceptScore W197747024C142724271 @default.
• W197747024 hasConceptScore W197747024C197934379 @default.
• W197747024 hasConceptScore W197747024C204787440 @default.
• W197747024 hasConceptScore W197747024C27081682 @default.
• W197747024 hasConceptScore W197747024C2777180221 @default.
• W197747024 hasConceptScore W197747024C2778375690 @default.
• W197747024 hasConceptScore W197747024C2778715236 @default.
• W197747024 hasConceptScore W197747024C2778763485 @default.
• W197747024 hasConceptScore W197747024C2779284873 @default.
• W197747024 hasConceptScore W197747024C2779306644 @default.
• W197747024 hasConceptScore W197747024C2780282729 @default.
• W197747024 hasConceptScore W197747024C2780323712 @default.
• W197747024 hasConceptScore W197747024C555293320 @default.
• W197747024 hasConceptScore W197747024C71924100 @default.
• W197747024 hasConceptScore W197747024C98274493 @default.
• W197747024 hasIssue "2" @default.
• W197747024 hasLocation W1977470241 @default.
• W197747024 hasLocation W1977470242 @default.
• W197747024 hasLocation W1977470243 @default.
• W197747024 hasOpenAccess W197747024 @default.
• W197747024 hasPrimaryLocation W1977470241 @default.
• W197747024 hasRelatedWork W1921395120 @default.
• W197747024 hasRelatedWork W1963999135 @default.
• W197747024 hasRelatedWork W1964984403 @default.
• W197747024 hasRelatedWork W1991565451 @default.
• W197747024 hasRelatedWork W2025436379 @default.
• W197747024 hasRelatedWork W2031540476 @default.
• W197747024 hasRelatedWork W2164282118 @default.
• W197747024 hasRelatedWork W2168411651 @default.
• W197747024 hasRelatedWork W2301714968 @default.
• W197747024 hasRelatedWork W2900884558 @default.
• W197747024 hasVolume "20" @default.
• W197747024 isParatext "false" @default.
• W197747024 isRetracted "false" @default.
• W197747024 magId "197747024" @default.
• W197747024 workType "article" @default.